Clinical Trial Update: Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial testing dabrafenib and trametinib with IMRT in patients with BRAF-mutated anaplastic thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present | Phase 1 | Status: RECRUITING